Close Menu

SiMoA

In a study published this week, researchers presented a Simoa-based assay for tuberculosis that could ultimately be packaged as a point-of-care test.

The company sold 2.2 million shares at an average price of $22.73 per share under a $50 million at-the-market equity facility it filed in March 2019.

The company posted Q1 revenues of $12.3 million, up from $7.5 million in Q1 2018 and above the consensus Wall Street estimate of $10.2 million.

They demonstrated the applicability of the Simoa platform for nucleic acid detection, and miRNA detection in particular, as Quanterix prepares to launch a new system.

Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.

The team's dilution experiments suggest Simoa could be thousands of times more sensitive than standard ELISAs in detecting anti-dengue antibodies.

A team led by researchers at the University of Gothenberg have published a study using Quanterix's Simoa technology to measure the brain protein tau in the blood of hockey players to assess brain injury due to concussions.

This article has been updated to include ImmunArray's participation in the program.

A research team at the University of Gothenburg in Sweden is using Quanterix's Single Molecule Array, or Simoa, platform to identify blood biomarkers related to brain injury.

Quanterix said this week that response to the launch last week of its research-use-only automated Single Molecule Array, or Simoa, platform has been enthusiastic – particularly among developers of laboratory-developed tests – and that it will ship the first of its systems to cust

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.